Incremental prognostic value of the fibrinogen−to−albumin ratio for adverse perinatal outcomes in preeclampsia: a dual−center retrospective cohort study - Takeaways - MDSpire

Incremental prognostic value of the fibrinogen−to−albumin ratio for adverse perinatal outcomes in preeclampsia: a dual−center retrospective cohort study

  • By

  • Xiaoyun Chen

  • Zhihong Wang

  • Yueqiong Wang

  • Huaijian Zhang

  • Yahui Liu

  • Yichao Pan

  • Ling Chen

  • Xun Zhang

  • Jiabin Li

  • Ye Huang

  • May 29, 2026

  • 0 min

Share

  • 1

    The study evaluates the prognostic value of the fibrinogen-to-albumin ratio (FAR) in predicting adverse perinatal outcomes in preeclamptic patients.

  • 2

    In a dual-center study of 924 preeclamptic patients, the addition of FAR to existing models improved prediction of composite adverse perinatal outcomes.

  • 3

    Model B, incorporating FAR, achieved an AUC of 0.888, significantly outperforming the base model's AUC of 0.852 in the training cohort.

  • 4

    FAR ≥0.135 indicates coagulopathy and systemic inflammation, guiding anesthesiology decisions for preeclamptic patients.

  • 5

    The findings support FAR as a valuable biomarker for risk stratification in preeclamptic patients, enhancing clinical decision-making.

Original Source(s)

Incremental prognostic value of the fibrinogen−to−albumin ratio for adverse perinatal outcomes in preeclampsia: a dual−center retrospective cohort study

  • by Xiaoyun Chen, Zhihong Wang, Yueqiong Wang, Huaijian Zhang, Yahui Liu, Yichao Pan, Ling Chen, Xun Zhang, Jiabin Li, Ye Huang

  • May 29, 2026

Related Content

The Ebola outbreak will lead to devastating violence against women and girls

Cell-dependent antithrombotic effect of tranexamic acid

Premature ovarian insufficiency in patients with systemic lupus erythematosus on cyclophosphamide: a systematic review and meta-analysis